Drug intelligence / Profile preview

DNT038

Development stage: Preclinical
Lead developer: Denteric
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

DNT038 is an investigational mRNA vaccine being developed by Denteric in collaboration with CSL and the University of Melbourne. It targets *Porphyromonas gingivalis*, a key bacterial pathogen associated with severe periodontal disease and potentially linked to systemic conditions such as Alzheimer's disease. The vaccine encodes specific *P. gingivalis* antigens to induce a protective immune response against the bacterium. It is currently in preclinical development for the treatment and prevention of periodontal disease and the investigation of its impact on Alzheimer's disease progression.

Other names: DNT038 mRNA vaccineDNT-038 mRNA vaccineDNT 038 mRNA vaccine

Targets

Kgp (Lysine gingipain)Rgp (Arginine gingipain)

Beyond the preview

Go deeper on DNT038.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNT038.

Explore the full profile